## Acetyl-Histone H3 (Lys56) Antibody



Orders: 877-616-CELL (2355)

orders@cellsignal.com

Support: 877-678-TECH (8324)

Web: info@cellsignal.com

cellsignal.com

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

## For Research Use Only. Not for Use in Diagnostic Procedures

Applications: W	<b>Reactivity:</b> H M R Mk	<b>Sensitivity:</b> Endogenous	<b>MW (kDa):</b> 17	<b>Source/Isotype:</b> Rabbit	UniProt ID: #P68431	Entrez-Gene Id: 8350
Product Usage	<b>!</b>	Application			Dilution	
Information		Western Blotting	1:1000			
Storage		Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 $\mu$ g/ml BSA and 50% glycerol. Store at – 20°C. Do not aliquot the antibody.				
Specificity/Sensitivity		Acetyl-Histone H3 (Lys56) Antibody detects endogenous levels of histone H3 only when acetylated on Lys56. This antibody does not cross-react with histone H3 acetylated on lysines 9, 14, 18 or 27.				
Source / Purification		Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to the amino terminus of histone H3 in which Lys56 is acetylated. Antibodies are purified by protein A and peptide affinity chromatography.				
Background		Modulation of chromatin structure plays an important role in the regulation of transcription in eukaryotes. The nucleosome, made up of DNA wound around eight core histone proteins (two each of H2A, H2B, H3, and H4), is the primary building block of chromatin (1). The amino-terminal tails of core histones undergo various posttranslational modifications, including acetylation, phosphorylation, methylation, and ubiquitination (2-5). These modifications occur in response to various stimuli and have a direct effect on the accessibility of chromatin to transcription factors and, therefore, gene expression (6). In most species, histone H2B is primarily acetylated at Lys9, 14, 18, 23, 27, and 56. Acetylation of H3 at Lys9 appears to have a				

H2A, H2B, H3, and H4), is the primary building block of chromatin (1). The amino-terminal tails of core histones undergo various posttranslational modifications, including acetylation, phosphorylation, methylation, and ubiquitination (2-5). These modifications occur in response to various stimuli and have a direct effect on the accessibility of chromatin to transcription factors and, therefore, gene expression (6). In most species, histone H2B is primarily acetylated at Lys5, 12, 15, and 20 (4,7). Histone H3 is primarily acetylated at Lys9, 14, 18, 23, 27, and 56. Acetylation of H3 at Lys9 appears to have a dominant role in histone deposition and chromatin assembly in some organisms (2,3). Phosphorylation at Ser10, Ser28, and Thr11 of histone H3 is tightly correlated with chromosome condensation during both mitosis and meiosis (8-10). Phosphorylation at Thr3 of histone H3 is highly conserved among many species and is catalyzed by the kinase haspin. Immunostaining with phospho-specific antibodies in mammalian cells reveals mitotic phosphorylation at Thr3 of H3 in prophase and its dephosphorylation during anaphase (11).

Acetylation of histone H3 on Lys56 is critical for proper packaging of DNA into chromatin during DNA replication and DNA damage repair (12-14). Histone H3 is acetylated on Lys56 by CBP and p300 in response to DNA damage induced by treatment of cells with  $\gamma$  radiation, ultraviolet light, MMS, or hydroxyurea (14). Following DNA damage, chromatin assembly factor 1 protein (CAF-1) incorporates acetylated histones into chromatin at sites of DNA repair (14). The class III histone deacetylases (HDACs) SirT1, SirT2 and SirT6 have been shown to deacetylate histone H3 at Lys56 (14,15); however, treatment of cells with sodium butyrate or trichostatin A also leads to increased acetylation, implicating a class I or class II HDAC as an additional histone H3 Lys56 deacetylase (14). Histone H3 Lys56 acetylation is high in multiple types of cancer, and acetylation levels directly correlate with cellular dedifferentiation and tumorigenicity (14).

## **Background References**

- 1. Workman, J.L. and Kingston, R.E. (1998) *Annu Rev Biochem* 67, 545-79.
- 2. Hansen, J.C. et al. (1998) *Biochemistry* 37, 17637-41.
- 3. Strahl, B.D. and Allis, C.D. (2000) Nature 403, 41-5.
- 4. Cheung, P. et al. (2000) Cell 103, 263-71.
- 5. Bernstein, B.E. and Schreiber, S.L. (2002) *Chem Biol* 9, 1167-73.
- 6. laskelioff, M. and Peterson, C.L. (2003) Nat Cell Biol 5, 395-9.
- 7. Thorne, A.W. et al. (1990) Eur J Biochem 193, 701-13.
- 8. Hendzel, M.J. et al. (1997) Chromosoma 106, 348-60.
- 9. Goto, H. et al. (1999) / Biol Chem 274, 25543-9.
- 10. Preuss, U. et al. (2003) Nucleic Acids Res 31, 878-85.
- 11. Dai, J. et al. (2005) Genes Dev 19, 472-88.
- 12. Chen, C.C. et al. (2008) *Cell* 134, 231-43.
- 13. Li, Q. et al. (2008) *Cell* 134, 244-55.
- 14. Das, C. et al. (2009) *Nature* 459, 113-7. 15. Yang, B. et al. (2009) *Cell Cycle* 8, 2662-3.

**Species Reactivity** Species reactivity is determined by testing in at least one approved application (e.g., western blot).

Western Blot Buffer IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X

TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.

Applications Key W: Western Blotting

Cross-Reactivity Key H: Human M: Mouse R: Rat Mk: Monkey

Trademarks and Patents Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.

All other trademarks are the property of their respective owners. Visit cellsignal.com/trademarks for

more information.

**Limited Uses**Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's

terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no

force or effect.

Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.